{"entity":{"id":"nct07700160","kind":"trial","name":"First-in-Human Trial of VBC108 in Participants With Advanced Malignant Solid Tumors","aka":[],"tldr":"A phase 1/2 trial of VBC108 in advanced solid tumours, run by VelaVigo Bio Inc, now recruiting.","summary":"First-in-Human Trial of VBC108 in Participants With Advanced Malignant Solid Tumors is a phase 1/2 interventional study registered as NCT07700160 by VelaVigo Bio Inc, with 230 participants planned, started 2026-07-30 and due to reach its primary completion in 2029-07-07. Interventions recorded: VBC108.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07700160","url":"https://clinicaltrials.gov/study/NCT07700160"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07700160","phase":"1/2","setting":"Phase 1/2a Open-label Clinical Trial Evaluating VBC108, a CLDN18.2 and CDH17-directed Bi-specific Antibody Drug Conjugate, in Participants With Advanced Malignant Solid Tumors","sponsor":"VelaVigo Bio Inc","enrolled":230,"outcomes":[]},"route":"/trials/nct07700160/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}]}}